{"celex_id": "31996D0318", "uri": "http://publications.europa.eu/resource/cellar/e7633d36-ed83-4487-9416-ef8d77751969", "type": "Decision", "concepts": ["1085", "1309", "2773", "5042", "6007", "863"], "title": "96/318/EC: Commission Decision of 20 December 1995 refusing France's application for protective measures with regard to pharmaceutical products coming from Spain (Only the French text is authentic)\n", "header": "COMMISSION DECISION of 20 December 1995 refusing France's application for protective measures with regard to pharmaceutical products coming from Spain (Only the French text is authentic) (96/318/EC)\nTHE COMMISSION OF THE EUROPEAN COMMUNITIES", "recitals": ",\nHaving regard to the Treaty establishing the European Community,\nHaving regard to the Act of Accession of Spain and Portugal, and in particular Article 379 thereof,\nHaving regard to the application by France,\nWhereas France, by letter of 29 September 1995, applied to the Commission for authorization to invoke Article 379 of the Act of Accession for safeguard measures, aimed at refusing the import into France of pharmaceutical products coming from Spain, which are protected in France by a product patent but not in Spain;\nWhereas in their request, the French authorities provided the Commission with the material facts to enable it to evaluate the validity of the application;\nWhereas the French authorities base their application upon the economic difficulties to which the pharmaceutical products market in France would be, according to them, subjected as a result of the expiry of the transitional period provided for by Article 47 of the Act of Accession, namely as from 7 October 1995; whereas the specialists argue that since the price of pharmaceuticals on the Spanish market is between 12 % and 100 % lower than the observed price for the same speciality products on the French market, the expiry of the transitional period will lead to an appreciable increase in parallel imports from Spain; whereas this increase will thus damage the market shares of French operators in the export market;\nWhereas Article 379 derogates from a fundamental principle of the EC Treaty, that of the free movement of goods; whereas consequently in accordance with the well-established case-law of the Court of Justice it should be restrictively interpreted;\nWhereas consequently, in accordance with that case-law and with the established practice of the Commission in the past, Article 379 cannot apply;\nWhereas the purpose of Article 379 is to rectify and adjust to the economy of the common market a given economic sector experiencing economic difficulties which are serious and liable to persist;\nWhereas an analysis of the economic data provided by the French authorities has shown that the conditions for the application of Article 379 are not fulfilled; whereas, more particularly, it has revealed that the French pharmaceutical industry is not experiencing economic difficulties which are serious and liable to persist; whereas an increase in the volume of imports coming from Spain of pharmaceutical products patented in France but not in Spain would not appear to be so significant in the long run as to bring about, by itself, serious economic difficulties on the French pharmaceutical market,", "main_body": ["The application for safeguard measures made by France under Article 379 of the Act of Accession, aimed at refusing the import into France of pharmaceutical products coming from Spain, which are protected by a product patent in France but not in Spain, is rejected.", "This Decision is addressed to the French Republic."], "attachments": "Done at Brussels, 20 December 1995.\nFor the Commission\nMario MONTI\nMember of the Commission"}